HOME >> BIOLOGY >> NEWS
Novel test identifies lymphoma patients likely to respond to new therapy

February 20, 2007 (Bronx, NY) Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients wholl be most likely to benefit from it.

The research was led by Dr. Ari Melnick, assistant professor of developmental & molecular biology and medicine at Einstein, who also developed the new lymphoma therapy. The study appears in the February 20 issue of the Proceedings of the National Academy of Sciences.

Each year more than 60,000 Americans are diagnosed with B cell lymphomastumors of cells of the immune system that include Hodgkins and non-Hodgkins lymphomas. B cells are the immune-system cells that make antibodies. Genetic aberrations can cause B cells to multiply uncontrollably, causing B cell lymphomas.

Dr. Melnicks study focused on a gene called BCL6. The protein it codes for is a transcriptional repressor, which means that it can shut off the functioning of genes in B cells and other cells of the immune system and prevent them from being expressed. The BCL6 protein is normally produced only during a specific stage of B cell development and is never made again. But deregulation of BCL6 can cause the protein to be produced when it shouldnt be. The unwelcome presence of the BCL6 protein blocks the expression of important genes that normally protect cells from becoming cancerous. As a result, malignant B-cell lymphomas occur.

Mutations or chromosomal rearrangements that deregulate BCL6 are responsible for many cases of diffuse large B cell lymphomaan aggressive cancer that accounts for up to 30 percent of newly diagnosed non-Hodgkins lymphoma cases. In a 2004 Nature Medicine article, Dr. Melnick and colleagues described a peptide, which they dubbed BPI, that showed pr
'"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
20-Feb-2007


Page: 1 2

Related biology news :

1. Novel sugar-to-hydrogen technology promises transportation fuel independence
2. Novel system developed to turn data into real-time, interactive 3-D images
3. Novel strategies for healthy aging
4. Novel salamander robot crawls its way up the evolutionary ladder
5. Novel laboratory technique nudges genes into activity
6. Novel approaches to tackling obesity, cancer and MRSA
7. Novel approach to cancer drug given major boost
8. Novel regulation of the common tumor suppressor PTEN
9. Novel EGFR ectodomain mutations in glioblastoma
10. Novel regulatory mechanism identified for key tumor suppressor p53
11. Novel experiment documents evolution of genome in near-real time

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... 2020 , ... Justin Zamirowski to lead upcoming launches of ... on Type 2 diabetes and associated comorbidities. , Justin brings over 20 years ... As Chief Commercial Officer, Justin will lead Better Therapeutics’ efforts in ...
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While the ... economic downturn will only increase price pressures overall for the industry. The era of ... every product launch is critical. However, history shows that only a third of product ...
(Date:7/4/2020)... ... , ... Aesthetics Biomedical (ABM), a leading aesthetics product development ... the products and treatments developed, but also the dedicated team behind the brands ... built by ABM have received several honors already for 2020, each of which ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... July 06, 2020 , ... ... from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, ... has hosted an elite awards program, highlighting outstanding examples of how technology innovations ...
(Date:6/28/2020)... ... 2020 , ... The Indoor Lab, a leading provider of sensor solutions for ... types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology using ... will provide a health performance index system that scores all aspects of compliance similar ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast Inc. , ... today announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. ... studies of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level ...
(Date:6/23/2020)... PORTLAND, Ore. (PRWEB) , ... June 23, 2020 ... ... advancement of innovative CNS therapies, today announced that it has filed an Investigational ... initiate a Phase 2b clinical trial of its lead drug candidate NBTX-001 in ...
Breaking Biology Technology:
Cached News: